The Countess of Chester Hospital NHS Foundation Trust~s Commercial Procurement Service seeks to introduce a new commercial framework agreement which will allow NHS authorities to procure the sleep mask for the treatment of Diabetic Retinopathy and Diabetic Macular Oedema
with no further competition.
To be able to explain to the patient about the implications of cystoid macular oedema
7] Chou TH et al, Relationship of diabetic macular oedema
with glycosylated haemoglobin.
occurs when fluid leaks from the small blood vessels in the eye and distorts vision.
1] Up to 25,000 patients in the UK every year suffer from macular oedema
associated with RVO and may be suitable for treatment with OZURDEX.
GlobalData, the industry analysis specialists new report, Macular Oedema
- Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global macular oedema
These messenger proteins cause inflammation which plays a role in CRVO-related macular oedema
UK regulator will draft the ultimate guidance and has endorsed the therapy for macular oedema
caused by central or branch retinal vein occlusion - common conditions that can affect a patient's ability to see detail and colour.
We would also like to see urgent testing into alternative treatments for diabetic macular oedema
1], Called the COmparison of intravitreal dexamethasone implant and ranibizumab for Macular Oedema
in BRVO (COMO), the objective of the study is to assess the relative effectiveness of two distinct therapies for BRVO, OZURDEX(R) (dexamethasone 0.
Professor Carole Longson (pictured), health technology evaluation centre director at NICE, said: "Around 336,000 people with diabetes in the UK have diabetic macular oedema
Lucentis is now available on the NHS in Scotland for the treatment of patients with wet AMD, visual impairment due to diabetic macular oedema
and visual impairment due to macular oedema
secondary to retinal vein occlusion, both central and branch.
First Licensed Treatment in 25 Years(1) for Diabetic Macular Oedema
, One of the Leading Causes of Visual Impairment in the UK Working Population(2) Launched Today
As part of Vision 2020 UK, the Macular Interest Group has written to senior officers in Clinical Commissioning Groups (CCGs) across England to highlight the rise in demand for the drug Lucentis, which is used to treat a number of retinal diseases, including macular oedema
First Licensed Treatment in 25 Years for Diabetic Macular Oedema
, One of the Leading Causes of Visual Impairment in the UK Working Population Launched Today